60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
May 20, 2024 07:59 ET
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
Hemispherx Biopharma Announces Collaboration with Millions Missing Canada to Bring Medication to Canadians for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
August 08, 2017 06:08 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) has announced that on Thursday, August 3, 2017 it participated in a meeting in Toronto, Canada with Canadian...
Hemispherx Encouraged by Cytokine Biomarker Discovery Which May Lead to a Diagnostic for Chronic Fatigue Syndrome
August 04, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 04, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) said today that a new study led by a team of researchers from Stanford University may provide the basis for a...
Hemispherx Biopharma Enhances Ampligen Manufacturing and Scientific Capabilities
May 31, 2017 11:38 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 31, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it continues to build its manufacturing and scientific...
A Hemispherx Biopharma anuncia um grande avanco: A aprovacão para comercializar o rintatolimode (nome comercial nos Estados Unidos: Ampligen®) para o tratamento de casos graves de Encefalomielite Miálgica/Síndrome da Fadiga Crônica (EM/SFC) na República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
O primeiro produto aprovado indicado para EM/SFC em qualquer parte do mundo Essa aprovação inédita significa um caminho aberto para o crescimento na América Latina e União Europeia ...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma anuncia un logro importante: aprobación de rintatolimod para la venta comercial (nombre comercial en EE. UU.: Ampligen®) para el tratamiento de casos severos de encefalomielitis miálgica/síndrome de fatiga crónica (EM/SFC) en la República Argentina
August 26, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
Primer producto aprobado para la indicación EM/SFC en todo el mundo Esta nueva aprobación abre paso para el crecimiento en Latinoamérica y la Unión Europea PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 26, 2016 01:00 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 26, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 25, 2016 20:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 25, 2016 (GLOBE...
Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic
August 23, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
First Product Approved for ME/CFS Indication Anywhere in the World Breakthrough Approval Provides Clear Path for Growth in Latin America and the European Union PHILADELPHIA, Aug. 23, 2016 (GLOBE...